A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

The present disclosure is directed to use of RORγt inhibitors in the treatment of autoimmune disorders, e.g., autoimmune disorders of the skin. This disclosure is also directed to pharmaceutical compositions comprising an RORγt inhibitor and a pharmaceutically acceptable carrier for topical administration.

The present disclosure is directed to use of RORγt inhibitors in the treatment of autoimmune disorders, e.g., autoimmune disorders of the skin. This disclosure is also directed to pharmaceutical compositions comprising an RORγt inhibitor and a pharmaceutically acceptable carrier for topical administration.

The present application relates to method of vaccinating a subject against infection by an enveloped virus. The method includes providing a compound of the Formula (I) as described herein, and contacting the compound of Formula (I) with an isolated enveloped virus, having a membrane, to inactivate the membrane of the isolated enveloped virus. The subject is then treated with the enveloped virus having an inactivated membrane to vaccinate the subject against the enveloped virus. Further disclosed is an ex vivo vaccine composition including the compound of Formula (I) and an enveloped virus.

The present application relates to method of vaccinating a subject against infection by an enveloped virus. The method includes providing a compound of the Formula (I) as described herein, and contacting the compound of Formula (I) with an isolated enveloped virus, having a membrane, to inactivate the membrane of the isolated enveloped virus. The subject is then treated with the enveloped virus having an inactivated membrane to vaccinate the subject against the enveloped virus. Further disclosed is an ex vivo vaccine composition including the compound of Formula (I) and an enveloped virus.

The present invention relates to a phytocomplex or natural concentrate rich in polyphenolic compounds such as hydroxytyrosol and 3,4-DHPA-EDA, derived from the waters from the pressing of olives for oil and/or olive pomace as residues of the olive milling process, for use in the reduction/attenuation of the symptoms and/or side effects associated with/caused by diabetes and/or the pathological conditions associated therewith.

The present invention relates to a phytocomplex or natural concentrate rich in polyphenolic compounds such as hydroxytyrosol and 3,4-DHPA-EDA, derived from the waters from the pressing of olives for oil and/or olive pomace as residues of the olive milling process, for use in the reduction/attenuation of the symptoms and/or side effects associated with/caused by diabetes and/or the pathological conditions associated therewith.

The present invention relates to a phytocomplex or natural concentrate rich in polyphenolic compounds such as hydroxytyrosol and 3,4-DHPA-EDA, derived from the waters from the pressing of olives for oil and/or olive pomace as residues of the olive milling process, for use in the reduction/attenuation of the symptoms and/or side effects associated with/caused by diabetes and/or the pathological conditions associated therewith.

Provided is an effective amount of a desialylation agent and an effective amount of an anti CD38 antibody for use in the treatment of multiple myeloma. This results in potentiated primary NK cell activity against the multiple myeloma cell. Also envisaged is a method of treating multiple myeloma in a subject in need thereof.

Provided is an effective amount of a desialylation agent and an effective amount of an anti CD38 antibody for use in the treatment of multiple myeloma. This results in potentiated primary NK cell activity against the multiple myeloma cell. Also envisaged is a method of treating multiple myeloma in a subject in need thereof.